Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study
by
Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C,
Newcorn J, Sallee FR, Sangal RB, Saylor K,
West S, Kelsey D, Wernicke J, Trapp NJ, Harder D.
Lilly Research Laboratories, Indianapolis, IN 46285, USA.
dmichelson@lilly.com
Am J Psychiatry 2002 Nov;159(11):1896-901

ABSTRACT

OBJECTIVE: The authors assessed the efficacy of once-daily atomoxetine administration in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD). METHOD: In a double-blind study, children and adolescents with ADHD (N=171, age range=6-16 years) were randomly assigned to receive 6 weeks of treatment with either atomoxetine (administered once daily) or placebo. RESULTS: Outcomes among atomoxetine-treated patients were superior to those of the placebo treatment group as assessed by investigator, parent, and teacher ratings. The treatment effect size (0.71) was similar to those observed in previous atomoxetine studies that used twice-daily dosing. Parent diary ratings suggested that drug-specific effects were sustained late in the day. Discontinuations due to adverse events were low (less than 3%) for both treatment groups, and no serious safety concerns were observed. CONCLUSIONS: Once-daily administration of atomoxetine is an effective treatment for children and adolescents with ADHD.

ADHD
Options
Reboxetine
Noradrenaline
NARIs and SSRIs
Drug companies
Tomoxetine and ADD
Is Strattera safe for kids?
Tomoxetine (Strattera) for ADHD
Tomoxetine as an antidepressant
Big Pharma meets Madison Avenue
Tomoxetine (Strattera) v methylphenidate (Ritalin)
Atomoxetine (Strattera): prescribing information (PDF)

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family